Contraindications to Starting Beta-Blockers in Hospitalized Patients

Absolute Contraindications

The American Heart Association recommends that beta-blockers should not be initiated in hospitalized patients with hemodynamic instability, decompensated heart failure, cardiogenic shock, severe bradycardia (heart rate <60 bpm), second- or third-degree heart block without a pacemaker, severe bronchospastic lung disease, or hypotension 1, 2
Beta-blocker allergy or documented intolerance is a contraindication for beta-blocker initiation 1
Bradycardia with heart rate less than 60 beats per minute on arrival or within 24 hours after arrival while not already on a beta-blocker is a contraindication for beta-blocker initiation 1
Second- or third-degree heart block on ECG without a functioning pacemaker is a contraindication for beta-blocker initiation 1, 2, 3
Marked first-degree AV block with PR interval greater than 0.24 seconds is a contraindication for beta-blocker initiation 2, 3
Cardiogenic shock on arrival or within 24 hours after arrival is a contraindication for beta-blocker initiation 1, 2, 3
Decompensated heart failure on arrival or within 24 hours after arrival is a contraindication for beta-blocker initiation 1, 2

Hypotension or hemodynamic instability is a contraindication for beta-blocker initiation 2, 3, 4
Signs of inadequate systemic perfusion are a contraindication for beta-blocker initiation 2, 5
Patients requiring inotropic support during their hospital course require particular caution when initiating beta-blockers 6, 4, 7

Severe bronchospastic lung disease is a contraindication for beta-blocker initiation 2

The COMMIT/CCC-2 trial demonstrated that early intravenous beta-blocker therapy in 45,852 AMI patients showed no mortality benefit and increased cardiogenic shock risk (5.0% vs 3.9%), particularly in the first 2 days of hospitalization 2, 3, 5

The American College of Cardiology recommends that beta-blocker initiation is recommended only after optimization of volume status and successful discontinuation of intravenous diuretics, vasodilators, and inotropic agents 6, 4, 7, 8

In patients with reduced ejection fraction experiencing acute decompensation while already on chronic beta-blocker therapy, continuation is recommended in most patients in the absence of hemodynamic instability or contraindications 6, 4, 7, 8

Oral beta-blockers should be started within the first 24 hours in stable patients without contraindications 1, 3, 9, 5
Intravenous beta-blockers should be avoided in the acute setting except for specific indications (ongoing chest pain with tachycardia or severe hypertension) in hemodynamically stable patients 2, 3, 5, 10
Start at low doses and only in stable patients 6, 4, 7, 8

Patients at high risk who warrant extreme caution include those with: older age, female sex, higher Killip class, lower blood pressure, higher heart rate, ECG abnormalities, and previous hypertension 2, 3, 5

Do not use intravenous beta-blockers routinely in acute presentations—the COMMIT trial demonstrated net harm from this approach 2, 3, 5
Do not initiate beta-blockers in patients with borderline hemodynamics even if they appear "stable"—wait for clear optimization 2, 5
Do not withhold beta-blockers solely based on COPD diagnosis—cardioselective agents are safe in mild-to-moderate disease 2